About PT-141 Legal

PT-141 Legal is an independent editorial project that publishes summaries of the peer-reviewed research literature on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The name 'Legal' in this site's title reflects the compound's regulatory history — bremelanotide is the first melanocortin receptor agonist to receive FDA approval (2019, Vyleesi, for HSDD in premenopausal women) — not any statement about the site's legal or clinical authority. This is an editorial position, not a healthcare service. We are a reading room, not a clinic.

PT-141 Legal publishes indexed summaries of the bremelanotide research literature: mechanism of action, clinical trial findings from the RECONNECT Phase 3 program and Phase 2 studies in men with erectile dysfunction, pharmacokinetic data, the adverse-event profile from the 43-study clinical development database, and recent 2022–2025 neuroscience work on MC4R signaling in sexual desire circuits. Every quantitative claim on this site is cited to a PubMed-indexed publication with a verifiable PMID or DOI. We summarize published research; we do not conduct, fund, or endorse any research program.

This site does not address sourcing, supply, prescribing, or clinical management of bremelanotide. Readers with clinical questions about the compound should consult a licensed healthcare provider.

The research record on this site is compiled from PubMed (pubmed.ncbi.nlm.nih.gov), PMC (pmc.ncbi.nlm.nih.gov), ClinicalTrials.gov, and peer-reviewed journals including the International Journal of Impotence Research, Journal of Sexual Medicine, Journal of Women's Health, Obstetrics and Gynecology, Journal of Clinical Investigation, Frontiers in Endocrinology, CNS Spectrums, and Annals of Pharmacotherapy. Every citation has been verified for the existence of the PMID and DOI listed. The site is updated to reflect the publication record through 2025.

This is an editorial product. It reflects the state of the published literature as of the date noted in each summary, not the full breadth of bremelanotide-related research globally. We focus on human clinical data, with preclinical mechanistic work cited where it provides essential context.

We maintain this site's editorial accuracy. If you find a citation error, a misquoted finding, or a factual inaccuracy in any summary on this site, you can report it via the contact page. We will review, correct, and update accordingly. Citation integrity is the standard this site is held to.